| Literature DB >> 36039308 |
Demiraw Bikila1, Tadesse Lejisa1, Yosef Tolcha1, Chala Bashea1, Mehari Meles1, Tigist Getahun1, Genet Ashebir1, Wossene Habtu1, Feyissa Challa1, Ousman Mohammed2, Melkitu Kassaw3, Adisu Kebede4, Letebrhan G/Egzeabher5, Endalkachew Befekadu6, Mistire Wolde7, Aster Tsegaye7.
Abstract
Background: Even though several factors affect reference intervals (RIs), company-derived values are currently in use in many laboratories worldwide. However, few or no data are available regarding serum proteins RIs, especially in resource-limited countries such as Ethiopia. Objective: To establish RIs for serum protein electrophoresis of apparently healthy adults in Addis Ababa, Ethiopia.Entities:
Keywords: Addis Ababa; Ethiopia; reference interval; serum protein electrophoresis
Year: 2022 PMID: 36039308 PMCID: PMC9419900 DOI: 10.2147/IJGM.S376450
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Socio-Demographic Characteristics of Study Participants in Addis Ababa, Ethiopia, 2020 (N=297; Male=124 and Female=173)
| Variables | Frequency | % | |
|---|---|---|---|
| Sex | Male | 124 | 41.75 |
| Female | 173 | 58.25 | |
| Age group (years) | 18–24 | 40 | 13.49 |
| 25–34 | 148 | 49.83 | |
| 35–44 | 60 | 20.20 | |
| 45–60 | 49 | 16.50 | |
| Total | 297 | 100 | |
Mean, Median with IQR of Serum Protein Electrophoresis of Apparently Healthy Adults in Addis Ababa, Ethiopia, 2020 (N=297; Male=124 and Female=173)
| Analytes | Unit | Sex | N | Range | Mean | 95% CI of Mean | Median | 25th–75th Percentile (IQR) | |
|---|---|---|---|---|---|---|---|---|---|
| Albumin | % g/dL | Male | 124 | 53.5–65.9 | 59.28 | 58.80,59.76 | 59.10 | 57.60–61.28 | =0.0003* |
| 3.9–5.9 | 4.83 | 4.77,4.89 | 4.80 | 4.60–5.0 | <0.0001** | ||||
| Female | 173 | 50.0–65.0 | 58.06 | 57.67,58.46 | 58.20 | 56.25–59.80 | |||
| 4.0–5.5 | 4.59 | 4.55,4.64 | 4.60 | 4.40–4.80 | |||||
| Combined | 297 | 50.0–65.9 | 58.57 | 58.26,58.88 | 58.50 | 56.8,60.4 | |||
| 3.9–5.9 | 4.69 | 4.66,4.73 | 4.70 | 4.50–4.90 | |||||
| Alpha-1 | % g/dL | Male | 124 | 2.6–5.8 | 4.23 | 4.13,4.33 | 4.10 | 3.82–4.68 | <0.0001* |
| 0.2–0.5 | 0.35 | 0.34,0.36 | 0.30 | 0.30–0.40 | =0.4735** | ||||
| Female | 173 | 3.0–6.0 | 4.53 | 4.46,4.62 | 4.50 | 4.2–4.9 | |||
| 0.2–0.5 | 0.36 | 0.35,0.37 | 0.40 | 0.30–0.40 | |||||
| Combined | 297 | 2.6–6.0 | 4.41 | 4.34,4.47 | 4.40 | 4.0,4.80 | |||
| 0.2–0.5 | 0.36 | 0.35,0.36 | 0.40 | 0.30–0.40 | |||||
| Alpha-2 | % g/dL | Male | 124 | 7–13.6 | 9.80 | 9.58,10.01 | 9.50 | 9.0–10.60 | <0.0001* |
| 0.6–1.2 | 0.80 | 0.77,0.82 | 0.80 | 0.70–0.90 | =0.0006** | ||||
| Female | 173 | 8–13 | 10.57 | 10.40,10.74 | 10.50 | 9.75–11.40 | |||
| 0.6–1.2 | 0.84 | 0.82,0.86 | 0.80 | 0.75–0.90 | |||||
| Combined | 297 | 7.0–13.6 | 10.25 | 10.11,10.40 | 10.20 | 9.30,11.10 | |||
| 0.6–1.2 | 0.82 | 0.81,0.84 | 0.80 | 0.70,0.90 | |||||
| Beta-1 | % g/dL | Male | 124 | 4.7–7.7 | 6.14 | 6.04,6.25 | 6.10 | 5.70–6.58 | =0.0015* |
| 0.4–0.7 | 0.50 | 0.49,0.51 | 0.50 | 0.50–0.50 | 0.8572** | ||||
| Female | 173 | 4.8–7.9 | 6.38 | 6.29,6.48 | 6.40 | 6.0–6.70 | |||
| 0.4–0.7 | 0.50 | 0.49,0.51 | 0.50 | 0.50–0.50 | |||||
| Combined | 297 | 4.7–7.9 | 6.28 | 6.21,6.36 | 6.30 | 5.90,6.70 | |||
| 0.4–0.7 | 0.50 | 0.49,0.51 | 0.50 | 0.50–0.50 | |||||
| Beta-2 | % g/dL | Male | 124 | 2.4–5.3 | 3.62 | 3.51,3.72 | 3.60 | 3.20–4.0 | =0.1372* |
| 0.2–0.5 | 0.29 | 0.28,0.31 | 0.30 | 0.30–0.30 | =0.0319** | ||||
| Female | 173 | 2.4–5.7 | 3.52 | 3.43,3.61 | 3.40 | 3.10–3.80 | |||
| 0.2–0.5 | 0.28 | 0.27,0.29 | 0.30 | 0.20–0.30 | |||||
| Combined | 297 | 2.4–5.7 | 3.56 | 3.49,3.63 | 3.50 | 3.20,3.90 | |||
| 0.2–0.5 | 0.29 | 0.28,0.29 | 0.30 | 0.20–0.30 | |||||
| Gamma | % g/dL | Male | 124 | 12–22 | 16.96 | 16.57,17.34 | 16.90 | 15.55–18.58 | =0.7145* |
| 0.80–2.1 | 1.38 | 1.34,1.43 | 1.40 | 1.20–1.50 | =0.1411** | ||||
| Female | 173 | 11.2–23 | 16.93 | 16.60,17.26 | 16.80 | 15.30–18.30 | |||
| 0.8–2.1 | 1.35 | 1.31,1.38 | 1.30 | 1.20–1.50 | |||||
| Combined | 297 | 11–23 | 16.94 | 16.69,17.19 | 16.90 | 15.45,18.30 | |||
| 0.8–2.1 | 1.36 | 1.34,1.39 | 1.40 | 1.20–1.50 | |||||
| A/G ratio | Male | 124 | 1.15–1.93 | 1.46 | 1.44,1.49 | 1.44 | 1.36–1.58 | =0.0005* | |
| Female | 173 | 1.0–1.86 | 1.39 | 1.37,1.42 | 1.39 | 1.28–1.49 | |||
| Combined | 297 | 1.0–1.93 | 1.42 | 1.41,1.44 | 1.41 | 1.31,1.53 | |||
Notes: p-Value: Mann–Whitney U-test for male versus female; *p-value for concentration expressed in percentage (%); **p-value for absolute concentration expressed in g/dL.
Abbreviations: CI, confidence interval; RI, reference interval; A/G ratio, albumin to globulin ratio.
Reference Interval with 90% CI of Reference Limits of Serum Protein Electrophoresis of Apparently Healthy Adults in Addis Ababa, Ethiopia, 2020 (N=297; Male=124 and Female=173)
| Analytes | Unit | Sex | N | Range | 2.5th–97.5th Percentile, RI | 90% CI (Lower Reference Limit) | 90% CI (Upper Reference Limit) |
|---|---|---|---|---|---|---|---|
| Albumin | % g/dL | Male | 124 | 53.5–65.9 | 53.83–64.59 | 53.5–54.5 | 63.5–65.9 |
| 3.9–5.9 | 4.31–5.89 | 3.90–4.40 | 5.30–5.90 | ||||
| Female | 173 | 50.0–65.0 | 52.24–63.55 | 50.0–53.6 | 62.0–65.0 | ||
| 4.0–5.5 | 4.10–5.20 | 4.0–4.20 | 5.10–5.50 | ||||
| Combined | 297 | 50.0–65.9 | 53.18–64.10 | 52.10–53.80 | 63.30–64.90 | ||
| 3.9–5.9 | 4.1–5.36 | 4.0–4.20 | 5.20–5.90 | ||||
| Alpha-1 | % g/dL | Male | 124 | 2.6–5.8 | 3.04–5.40 | 2.60–3.50 | 5.20–5.80 |
| 0.2–0.5 | 0.21–0.50 | 0.20–0.30 | 0.50–0.50 | ||||
| Female | 173 | 3.0–6.0 | 3.44–5.60 | 3.0–3.70 | 5.5–6.0 | ||
| 0.2–0.5 | 0.30–0.50 | 0.20–0.30 | 0.50–0.50 | ||||
| Combined | 297 | 2.6–6.0 | 3.4–5.6 | 3.0–3.50 | 5.40–5.80 | ||
| 0.2–0.5 | 0.30–0.50 | 0.2–0.3 | 0.5–0.5 | ||||
| Alpha-2 | % g/dL | Male | 124 | 7–13.6 | 8.0–12.67 | 7.0–8.10 | 12.10–13.60 |
| 0.6–1.2 | 0.60–1.1 | 0.60–0.70 | 1.10–1.20 | ||||
| Female | 173 | 8–13 | 8.44–12.87 | 7.90–8.60 | 12.50–13.30 | ||
| 0.6–1.2 | 0.64–1.10 | 0.60–0.70 | 1.0–1.20 | ||||
| Combined | 297 | 7.0–13.6 | 8.04–12.76 | 7.90–8.30 | 12.5–13.3 | ||
| 0.6–1.2 | 0.60–1.10 | 0.6–0.7 | 1.10–1.10 | ||||
| Beta-1 | % g/dL | Male | 124 | 4.7–7.7 | 5.01–7.38 | 4.80–5.20 | 7.30–7.90 |
| 0.4–0.7 | 0.40–0.69 | 0.40–0.40 | 0.60–0.70 | ||||
| Female | 173 | 4.8–7.9 | 5.14–7.86 | 4.80–5.30 | 7.30–7.90 | ||
| 0.4–0.7 | 0.40–0.66 | 0.36–0.40 | 0.60–0.70 | ||||
| Combined | 297 | 4.7–7.9 | 5.10–7.56 | 4.80–5.20 | 7.30–7.90 | ||
| 0.4–0.7 | 0.40–0.66 | 0.40–0.40 | 0.60–0.70 | ||||
| Beta-2 | % g/dL | Male | 124 | 2.4–5.3 | 2.70–4.89 | 2.40–2.90 | 4.70–5.30 |
| 0.2–0.5 | 0.20–0.49 | 0.20–0.20 | 0.40–0.50 | ||||
| Female | 173 | 2.4–5.7 | 2.50–4.96 | 2.40–2.60 | 4.80–5.70 | ||
| 0.2–0.5 | 0.20–0.40 | 0.20–0.20 | 0.40–0.50 | ||||
| Combined | 297 | 2.4–5.7 | 2.54–4.90 | 2.40–2.70 | 4.80–5.40 | ||
| 0.2–0.5 | 0.20–0.40 | 0.20–0.20 | 0.40–0.50 | ||||
| Gamma | % g/dL | Male | 124 | 12–22 | 12.05–21.43 | 11.70–13.10 | 20.80–21.70 |
| 0.80–2.1 | 0.91–1.90 | 0.80–1.0 | 1.80–2.10 | ||||
| Female | 173 | 11.2–23 | 12.58–22.26 | 11.20–13.70 | 21.0–23.0 | ||
| 0.8–2.1 | 0.90–1.86 | 0.80–1.0 | 1.80–2.10 | ||||
| Combined | 297 | 11–23 | 12.40–21.66 | 11.70–13.10 | 20.90–22.80 | ||
| 0.8–2.1 | 0.90–1.90 | 0.80–1.0 | 1.80–2.0 | ||||
| A/G ratio | Male | 124 | 1.15–1.93 | 1.16–1.81 | 1.15–1.2 | 1.73–1.93 | |
| Female | 173 | 1.0–1.86 | 1.09–1.74 | 1.0–1.16 | 1.63–1.86 | ||
| Combined | 297 | 1.0–1.93 | 1.14–1.77 | 1.09–1.16 | 1.72–1.85 | ||
Abbreviations: RI, reference interval; CI, confidence interval; A/G ratio, albumin to globulin ratio.
Comparison of Serum Protein Electrophoresis RIs of Apparently Healthy Adults in Addis Ababa, Ethiopia, with Manufacturer Ranges and Published RIs
| References | Instrument (Software Version) | N | Age (Years) | Albumin | Alpha-1 | Alpha-2 | Beta-1 | Beta-2 | Gamma | A/G Ratio | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (Current Study) | Capillarys (9.2.0) | M | 124 | 18–65 | 53.83–64.59 | 3.04–5.40 | 8.00–12.67 | 5.01–7.38 | 2.70–4.89 | 12.05–21.43 | 1.16–1.81 |
| F | 173 | 18–65 | 52.24–63.55 | 3.44–5.60 | 8.44–12.87 | 5.14–7.86 | 2.50–4.96 | 12.58–22.26 | 1.09–1.74 | ||
| C | 297 | 18–65 | 53.18–64.10 | 3.40–5.60 | 8.04–12.76 | 5.10–7.56 | 2.54–4.90 | 12.40–21.66 | 1.14–1.77 | ||
| Sebia, France | Capillarys (5.2.1) | 246 | NA | 55.8–66.1 | 2.9–4.9 | 7.1–11.8 | 4.7–7.2 | 3.2–6.5 | 11.1–18.8 | NA | |
| USA | Paragon | NA | NA | 52–67 | 3.8–8.3 | 5.8–12.4 | NA | NA | 9.3–20.4 | NA | |
| Belgium | Paragon (1.08) | M | 82 | 18–65 | 60–70 | 3.9–6.4 | 4.9–9.3 | NA | NA | 7.9–18.3 | NA |
| F | 79 | 18–65 | 56–70 | 3.6–7.4 | 5.6–9.7 | NA | NA | 7.9–18.3 | NA | ||
| Switzerland | Paragon | NA | NA | 57–70 | 3.8–7.8 | 4.4–10.0 | NA | NA | 9.0–17.4 | NA | |
| Japan | Paragon (1.16) | 63 | NA | 56–69 | 3.9–6.3 | 4.8–8.4 | NA | NA | 9.9–21.5 | NA | |
| Italy | Paragon | 167 | NA | 54–68 | 3.7–8.8 | 5.5–11.7 | NA | NA | 10–20.3 | NA | |
| NA | 53–70 | 4.4–9.3 | 6.4–10.3 | NA | NA | 11–16.8 | NA | ||||
| Italy | Paragon (1.6) | NA | NA | 52.3–68.9 | 4.8–9.8 | 8.9–12.8 | NA | NA | 10.4–16.2 | NA | |
| Belgium | Capillarys (1.41) | 50 | NA | 55.6–66 | 2.0–6.9 | 5.9–11.4 | NA | NA | 8.0–18.8 | NA | |
| France | Capillarys (4.14) | M | 60 | NA | 50.5–62.7 | 4.8–8.3 | 7.1–12.2 | NA | NA | 10.2–18.5 | NA |
| F | 60 | ||||||||||
Abbreviations: RI, reference interval; M, male; F, female; C, combined; A/G ratio, albumin to globulin ratio; NA, not available.